Aeterna Zentaris Announces Details Regarding Transaction with Ceapro

Core Viewpoint - Aeterna Zentaris Inc. has finalized details regarding its merger with Ceapro Inc., including share consolidation and adjustments to the exchange ratio for shareholders [1][5]. Group 1: Merger Details - The merger transaction is described as a "merger of equals" between Aeterna and Ceapro [1]. - A share consolidation was completed on May 3, 2024, with a ratio of one post-consolidation common share for every four pre-consolidation shares [1]. - The adjusted exchange ratio for Ceapro shareholders is now 0.02360 of a common share for each Ceapro share held [1]. Group 2: Transaction Warrants - Holders of common shares as of May 29, 2024, will receive 0.47698 of a common share purchase warrant for each post-consolidation common share on May 31, 2024 [2]. - The Toronto Stock Exchange and Nasdaq will trade the common shares on a due bill basis from May 29, 2024, to May 31, 2024, ensuring purchasers receive the entitlement to the transaction warrants [3]. - Ex-distribution trading will commence on June 3, 2024, after which purchases will no longer include the entitlement to transaction warrants [3]. Group 3: Shareholder Actions - Shareholders will not need to take any action regarding the issuance of transaction warrants, as Aeterna will send out direct registration system advice statements to registered shareholders [4]. - Non-registered shareholders will have their accounts updated automatically by their investment dealers to reflect the transaction warrants [4]. Group 4: Company Overview - Aeterna Zentaris is a specialty biopharmaceutical company focused on developing and commercializing pharmaceutical and diagnostic products for significant unmet medical needs [6]. - The company's lead product, macimorelin, is the first and only FDA and European Commission approved oral test for diagnosing adult growth hormone deficiency [6]. - Aeterna is also developing therapeutic assets for various conditions, including neuromyelitis optica spectrum disorder, Parkinson's disease, hypoparathyroidism, and amyotrophic lateral sclerosis [7].